Skip to content

EV / sales at other companies

Emergent Biosolutions logo
Emergent BiosolutionsEBS
1.3×+0.4×
Opko Health logo
Opko HealthOPK
1.6×-0.1×
Merck & Co. logo
Merck & Co.MRK
5.2×+1.2×
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
55.3×+54.8×
Septerna, Inc. logo
Septerna, Inc.SEPN
14.3×-59.7×
Charles River Laboratories logo
Charles River LaboratoriesCRL
2.8×+0.2×

Other financials

Income statement

See full
Revenue$6.2M-11.3%
Gross profit$3.3M-52.0%
Operating income-$5.3M-136%
Net income-$3.5M-746%
EPS (diluted)-$0.05-400%

Balance sheet

See full
Cash & equivalents$145.6M-10.3%
Total debt$601.0K-50.6%
Total equity$151.6M-29.8%
Total assets$219.4M-11.2%

Cash flow

See full
Operating cash flow-$8.7M-223%
CapEx--100%
Free cash flow-$8.7M-223%

Valuation

See full
Market cap$261.08M-44.3%
Enterprise value$116.11M-59.6%
P/E10.3×+3.8×
P/S2.8×+0.2×

Profitability

See full
Gross margin65.4%-11.2pp
Operating margin52.4%-7.8pp
Net margin43.2%-6.1pp
FCF margin66.2%

Returns & leverage

See full
Return on equity39.9%-18.5pp
Debt / equity0.0×
Current ratio3.2×-5.2×

Where this comes from

Calculated from SIGA Technologies’s reported figures.

Based on the most recent quarter.

The official record: SIGA Technologies’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about SIGA Technologies's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SIGA Technologies's EV / sales?
SIGA Technologies (SIGA) reported EV / sales of 2.5× in Q1 2026.
How has SIGA Technologies's EV / sales changed year-over-year?
SIGA Technologies's EV / sales increased by 32.7% year-over-year, from 1.9× to 2.5×.
What is the long-term trend for SIGA Technologies's EV / sales?
Over 2 years (2023 to 2025), SIGA Technologies's EV / sales has grown at a 29.9% compound annual growth rate (CAGR), from 1.8× to 3×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.